CVS Health upgraded at TD Cowen after insurer unveils 2025 Medicare Advantage plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bernstein SocGen Group Upgrades Humana (HUM) to Outperform
October 8, 2024 5:50 AM EDTBernstein SocGen Group analyst Lance Wilkes upgraded Humana (NYSE: HUM) from Market Perform to Outperform with a price target of $308.00 (from $405.00).
The analyst comments "We are updating our model, decreasing our target price, but upgrading our rating to Outperform based on a view that risks are being incorporated into expectations and price, coupled with improving sector outlook and potential upside catalysts. Upgrading HUM, our investment thesis - We believe HUM is now an attractive... More
TD Cowen Downgrades Humana (HUM) to Hold
October 7, 2024 5:29 AM EDTTD Cowen analyst Gary Taylor downgraded Humana (NYSE: HUM) from Buy to Hold with a price target of $261.00 (from $402.00).
The analyst comments "We are downgrading Humana from a Buy to Hold rating. Despite MA plans' ability to reprice the business each year (and... More
